MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

First Posted Date
2020-06-19
Last Posted Date
2020-06-19
Lead Sponsor
wang, jianxiang
Target Recruit Count
50
Registration Number
NCT04440267
Locations
🇨🇳

HBDH, Tianjin, Tianjin, China

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Phase 2
Recruiting
Conditions
Triple Negative Breast Cancer
Interventions
Drug: Epirubicin or Pirarubicin
Drug: Cyclophosphamide
First Posted Date
2020-06-18
Last Posted Date
2020-06-18
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
286
Registration Number
NCT04437160
Locations
🇨🇳

Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2
Recruiting
Conditions
Marginal Zone Lymphoma
Interventions
Drug: Bortezomib
Drug: Rituximab
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Prednisone
First Posted Date
2020-06-16
Last Posted Date
2023-05-18
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
60
Registration Number
NCT04433156
Locations
🇨🇳

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2
Completed
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2020-06-16
Last Posted Date
2024-05-31
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT04432506
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

First Posted Date
2020-06-16
Last Posted Date
2020-06-16
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
81
Registration Number
NCT04432714
Locations
🇨🇳

The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Phase 1
Recruiting
Conditions
Cancer, Gastrointestinal
Gall Bladder Cancer
Stomach Cancer
Gastrointestinal Epithelial Cancer
Gastrointestinal Neoplasms
Cancer of Gastrointestinal Tract
Gastrointestinal Cancer
Pancreatic Cancer
Colo-rectal Cancer
Colon Cancer
Interventions
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Tumor-Infiltrating Lymphocytes (TIL)
Drug: Aldesleukin
First Posted Date
2020-06-11
Last Posted Date
2023-03-03
Lead Sponsor
Intima Bioscience, Inc.
Target Recruit Count
20
Registration Number
NCT04426669
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Phase 1
Recruiting
Conditions
PTCL, NOS
AITL
ALK- ALCL
Phase III-IV ALK+ ALCL
EATL
Interventions
Drug: Lenalidomide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
First Posted Date
2020-06-09
Last Posted Date
2020-06-16
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
91
Registration Number
NCT04423926
Locations
🇨🇳

The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Phase 2
Active, not recruiting
Conditions
Triple Negative Breast Cancer
Interventions
Drug: epirubicin hydrochloride
Drug: Cyclophosphamide
Drug: Albumin bound paclitaxel
Drug: Toripalimab
First Posted Date
2020-06-05
Last Posted Date
2024-05-21
Lead Sponsor
Fudan University
Target Recruit Count
70
Registration Number
NCT04418154
Locations
🇨🇳

Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

Phase 1
Withdrawn
Conditions
Recurrent Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Refractory Breast Carcinoma
Interventions
Drug: Cyclophosphamide
Biological: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM
Biological: Pembrolizumab
Biological: Recombinant Interferon Alpha 2b-like Protein
Other: Questionnaire Administration
Other: Quality of Life Assessment
First Posted Date
2020-06-05
Last Posted Date
2021-06-07
Lead Sponsor
Thomas Jefferson University
Registration Number
NCT04418219
Locations
🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Phase 1
Recruiting
Conditions
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions
Genetic: ALLO-501A
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2020-06-04
Last Posted Date
2024-06-06
Lead Sponsor
Allogene Therapeutics
Target Recruit Count
160
Registration Number
NCT04416984
Locations
🇺🇸

Northside Hospital - Atlanta, Atlanta, Georgia, United States

🇺🇸

Augusta University, Augusta, Georgia, United States

🇺🇸

Loyola University Medical Center, Maywood, Illinois, United States

and more 36 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy